Clinical Inquiries

Is osteoporosis screening in postmenopausal women effective?

Author and Disclosure Information

 

References

EVIDENCE-BASED ANSWER

No single study evaluates the effectiveness of osteoporosis screening. However, screening women over the age of 65 years—or those between 60–64 years with certain risk factors—is recommended based on available evidence.

First, osteoporosis is common, and its prevalence increases with age (strength of recommendation [SOR]: A—prospective cohort studies). Second, low bone mineral density predicts fracture risk (SOR: A—prospective cohort studies). Finally, the likelihood of osteoporotic fracture is reduced with therapy, such as alendronate 10 mg/day or risedronate 5 mg/day plus adequate daily calcium and vitamin D (SOR: A—meta-analysis of randomized clinical trials).

Women under 60 years should not be screened (SOR: B—clinical decision rule). There is no evidence to guide decisions about screening interval or at what age to stop screening. The long-term risks of newer medications used for osteoporosis are unknown.

Evidence summary

Osteoporosis results in significant morbidity and mortality. In a prospective observational study of women over 50 years of age, 39.6% had osteopenia and 7.2% had osteoporosis. Osteoporosis was associated with a fracture rate 4 times that of normal bone mineral density.1 People with vertebral or hip fractures have a reduced relative 5-year survival of 0.81. Excess mortality occurred within the first 6 months following fracture.2

One prospective cohort study identified 14 independent risk factors for hip fracture.3 The best predictors were female gender, age, low weight, and no current estrogen use. For women aged >65 years with no other risks, 12% to 28% have osteoporosis.4 Multiple risk assessment scales have been studied to identify women aged >65 years who are at increased risk; however, none of the scales had good discriminatory performance.5 As a result, it is unclear which factors for women under 65 years should trigger screening.

While multiple technologies exist to measure bone mineral density, dual-energy x-ray absorptiometry (DEXA) has been the most validated test for predicting fractures. A meta-analysis of 11 prospective cohort trials showed that all sites of bone mineral density measurements correlated with fractures (relative risk [RR], 1.5; 95% confi-dence interval [CI], 1.4–1.6.). However, DEXA of the femoral neck predicted hip fracture better than other measures (RR, 2.6; 95% CI, 2.0–3.5).6

Additionally, heel ultrasonography was compa-rable with hip DEXA for predicting hip fractures for women over 65 years (probability of fracture 0.018 vs. 0.023); no studies have compared effec-tiveness for women under 65 years.

Multiple therapeutic interventions for osteo-porosis have been demonstrated to reduce frac-tures. Adequate calcium and vitamin D appear to prevent fractures. Alendronate and rise-dronate are the only prescription medications with evidence showing they prevent hip fractures.

A meta-analysis of 11 randomized controlled trials including 11,808 women found fewer hip fractures in women taking 10 mg/day of alendronate (RR, 0.51; 95% CI, 0.38–0.69; number needed to treat [NNT]=24), and fewer vertebral fractures in women taking 5 mg/day of alendronate (RR, 0.52; 95% CI, 0.43–0.65; NNT=72).7

For these results to apply to screening, study participants must be similar to those identified by general population screening. All trials included healthy women with low bone mineral density who were not using estrogen, which is similar to women identified by general screening. However, 57% of women recruited for the second Fracture Intervention Trial (FIT-II), the largest study, were classified as ineligible. This raises concern about the study’s generalizability.8

The US Preventive Services Task Force did an outcomes estimation of screening effectiveness, combining all of the above data (Table).9 Screening 731 women aged 65 to 69 years would prevent 1 hip fracture if those with indications for treat-ment took it; screening 248 women would prevent 1 vertebral fracture. As the table demonstrates, benefits increase with age. For women under 65 years, benefits are relatively small, unless they have other risk factors for osteoporosis.

TABLE
Hip and vertebral fracture outcomes for osteoporosis screening in 10,000 postmenopausal women
9

Age (years)
Screening outcomes55–5965–6975–79
Identified with osteoporosis44512002850
Hip fracture prevented with medication21470
NNS to prevent 1 hip fracture4338731143
NNT to prevent 1 hip fracture1938841
Vertebral fractures prevented740134
NNS to prevent 1 vertebral fracture133824875
NNT to prevent 1 vertebral fracture603021
The calculations in this table assume that treatment reduces the risk of vertebral fracture by 48%, the risk of hip fracture to 36%, and that 70% of patients will adhere to therapy. Table modified from USPSTF report.9
NNS, number needed to screen for benefit; NNT, number needed to treat for benefit

Pages

Evidence-based answers from the Family Physicians Inquiries Network

Recommended Reading

Who should have colposcopy?
MDedge Family Medicine
Which postmenopausal women should be offered combined HRT?
MDedge Family Medicine
Does cranberry juice prevent or treat urinary tract infection?
MDedge Family Medicine
Do calcium supplements prevent postmenopausal osteoporotic fractures?
MDedge Family Medicine
Cancer recurrence and mortality in women using hormone replacement therapy after breast cancer: Meta-analysis
MDedge Family Medicine
Metronidazole gel ineffective for minimally abnormal Pap
MDedge Family Medicine
Vaccine prevents genital herpes in subgroup of women
MDedge Family Medicine
Densitometry identifies women in whom treatment will reduce fracture risk
MDedge Family Medicine
Self-examination does not reduce breast cancer mortality
MDedge Family Medicine
Does C-reactive protein predict cardiovascular events in women better than LDL?
MDedge Family Medicine